BGC201531

CAS No. 1186532-61-5

BGC201531( GTPL3380 | AP-1531 | BGC-20-1531 )

Catalog No. M23357 CAS No. 1186532-61-5

BGC201531 is a EP4 antagonist for the treatment of acute migraine.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 320 In Stock
10MG 466 In Stock
25MG 776 In Stock
50MG 1051 In Stock
100MG 1423 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BGC201531
  • Note
    Research use only, not for human use.
  • Brief Description
    BGC201531 is a EP4 antagonist for the treatment of acute migraine.
  • Description
    BGC201531 is a EP4 antagonist for the treatment of acute migraine.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    GTPL3380 | AP-1531 | BGC-20-1531
  • Pathway
    GPCR/G Protein
  • Target
    Prostaglandin Receptor
  • Recptor
    EP4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1186532-61-5
  • Formula Weight
    496.58
  • Molecular Formula
    C26H28N2O6S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC1=CC=CC=C1S(=O)(=O)[N-]C(=O)C2=CC(=C(O2)C)COC3=CC=C(C=C3)C4=NC=C(C=C4)OC.[Na+]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Czigler A , Toth L , Szarka N , et al. Prostaglandin E2, a postulated mediator of neurovascular coupling, at low concentrations dilates whereas at higher concentrations constricts human cerebral parenchymal arterioles[J]. Prostaglandins & other lipid mediators, 2019, 146:106389.
molnova catalog
related products
  • Terbogrel

    Terbogrel is an oral thromboxane A2 receptor antagonist (IC50 is about 10 nM) and thromboxane A2 synthase inhibitor (IC50 is about 10 nM).

  • ONO-AE3-208

    ONO-AE3-208 is an EP4 antagonist. It suppresses cell migration, invasion, and metastasis of prostate cancer.

  • 2-Acetylbenzoic acid

    2-Acetylbenzoic acid is more potent than 2-propionyloxybenzoic acid in inhibiting platelet function and platelet prostaglandin (PG) synthesis although the potencies of these agents were comparable in inhibiting prostacyclin (PGI2) synthesis.